<p>增加财富并更好地为退休做准备的最佳方法是积累优质成长股，以便长期持有。随着这些公司稳定地增长其收入和利润，它们的价值也会随之提升，投资者愿意为其支付更高的价格。随着时间的推移，它们的股价将持续上涨，从而为您带来可观的资本收益，同时您也会看到投资组合价值的持续增长。</p>
<p>更好的是，您应该选择那些不仅适合多年持有，而且适合终身持有的公司。这些企业需要具备几个重要的定义特征。它们应该展现出强劲的增长记录，拥有能够赢得忠诚度的知名品牌，并享有能够使业务随着时间稳步增长的催化剂。</p>
<p>在这些关键要素到位的情况下，以下是您可以考虑购买的三只优质成长股。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDg3NTYvY29udGludW91cy1nbHVjb3NlLW1vbml0b3IuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDg3NTYvY29udGludW91cy1nbHVjb3NlLW1vbml0b3IuanBnJnc9NzAw"/></p>
<p>图片来源：Getty images。</p>
<h2>1. Skechers</h2>
<p><strong>Skechers</strong>(SKX 0.33%) 设计、制造和销售一系列适合男性、女性和儿童的运动服装和鞋类。该公司通过全球超过 180 个国家的约 5300 家零售店销售其产品。Skechers 多年来成功地增长了其收入和净利润，如下表所示。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>74 亿美元</td>
<td>80 亿美元</td>
<td>90 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>5.466 亿美元</td>
<td>7.847 亿美元</td>
<td>9.043 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>3.73 亿美元</td>
<td>5.457 亿美元</td>
<td>6.395 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>(1.207 亿美元)</td>
<td>9.074 亿美元</td>
<td>无信息</td>
</tr>
</tbody>
</table>
<p>数据来源：Skechers。财政年度截至 12 月 31 日。</p>
<p>首席运营官 David Weinberg 将业绩归因于 Skechers 强大的产品线，强调舒适、风格和以合理价格提供的质量。首席执行官 Robert Greenberg 补充说，Skechers 广泛的产品组合吸引了不同年龄和性别的消费者，其针对篮球、足球和高尔夫等运动的表现部门仍具有显著的全球增长潜力。</p>
<p>Skechers 概述了其到 2026 年实现 100 亿美元销售额的增长计划。该计划涉及三个关键支柱：国际扩张、直接面向消费者（DTC）销售增长和国内增长。公司计划通过在新市场扩展其电子商务平台，同时多样化其产品供应，来实现低至中等的国际销售增长。</p>
<p>投资者可以放心，管理层已经制定了有效的多年度增长计划，并进行了适当的投资，以应对未来更强劲的需求。</p>
<h2>2. Stryker</h2>
<p><strong>Stryker</strong>(SYK -0.70%) 是一家医疗技术公司，提供医疗和外科设备、神经技术和骨科领域的产品和服务。Stryker 多年来在收入、净收入和自由现金流方面报告了持续增长，如下表所示。请注意，投资者应关注不包括特殊项目的净收入，以更好地了解公司核心业务的增长情况。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>184.49 亿美元</td>
<td>204.98 亿美元</td>
<td>225.95 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>28.41 亿美元</td>
<td>38.88 亿美元</td>
<td>36.89 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>23.58 亿美元</td>
<td>31.65 亿美元</td>
<td>29.93 亿美元</td>
</tr>
<tr>
<td>净收入（不含特殊项目）</td>
<td>26.28 亿美元</td>
<td>32.10 亿美元</td>
<td>39.70 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>20.36 亿美元</td>
<td>31.36 亿美元</td>
<td>34.87 亿美元</td>
</tr>
</tbody>
</table>
<p>数据来源：Stryker。财政年度截至 12 月 31 日。EI 代表 “特殊项目”。</p>
<p>这种持续的自由现金流生成使得这家医疗技术公司自 2009 年以来能够不断增加其股息。Stryker 最近的季度股息为 0.84 美元，比一年前的 0.80 美元增长了 5%。</p>
<p>该公司看起来将继续增长，报告显示其产品在所处市场的需求强劲。该业务预计 2025 年的有机销售增长将在 8% 到 9% 之间，并在 2023 年投资者日上宣布了长期有机销售增长目标约为每年 11%。该业务还通过收购来增长，以增强其产品和服务组合。</p>
<p>2023 年投资者日还强调了今年约两个百分点的稳定营业利润率扩张和每年约 0.3 个百分点的增长，调整后的每股收益实现了两位数的增长。管理层还计划将约 70% 到 80% 的调整后净收益转化为自由现金流，这将有助于推动 Stryker 年度股息的持续增长。</p>
<h2>3. DexCom</h2>
<p><strong>DexCom</strong>(DXCM 0.64%) 是一家医疗设备公司，利用技术帮助糖尿病患者跟踪其葡萄糖水平。DexCom 制造连续血糖监测仪（CGM），为其客户提供个性化解决方案。</p>
<p>随着全球糖尿病患者数量的增加，预计到 2045 年 20 至 79 岁成年人将达到 7.83 亿，DexCom 的 CGM 解决方案需求不断增加。该公司报告了 2022 年至 2024 年期间收入、净收入和自由现金流的持续增长，如下表所示。</p>
<table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>29.10 亿美元</td>
<td>36.22 亿美元</td>
<td>40.33 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>3.912 亿美元</td>
<td>5.977 亿美元</td>
<td>6 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>3.412 亿美元</td>
<td>5.415 亿美元</td>
<td>5.762 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>3.047 亿美元</td>
<td>5.119 亿美元</td>
<td>6.307 亿美元</td>
</tr>
</tbody>
</table>
<p>数据来源：DexCom。财政年度截至 12 月 31 日。</p>
<p>对于 2025 年，DexCom 预计总收入为 46 亿美元，这将代表 14% 的同比增长。</p>
<p>对于公司来说，推动连续血糖监测（CGM）成为所有胰岛素使用阶段的标准护理仍然处于早期阶段。DexCom 在 2024 年将其用户基础增长了约 25%，全球客户数量达到约 280 万至 290 万，但管理层认为这只是冰山一角。</p>
<p>仅在美国，就有超过 450 万人正在使用胰岛素并且可以报销（即，他们可以申请保险），但并未使用 CGM。此外，2 型非胰岛素患者的美国市场规模超过 2500 万，而当前 CGM 的渗透率仅为 5%。我们甚至还没有谈到糖尿病前期市场，估计约有 9800 万人，CGM 的渗透率不到 1%。</p>
<p>根据这些数据，显然 DexCom 仍然有很长的增长空间来应对糖尿病的困扰。</p>
<p>该公司的 Stelo 产品于 2024 年 3 月获得批准，是美国首个获准无处方使用的葡萄糖生物传感器。自去年 8 月推出以来，该产品现已拥有 14 万用户，其中大多数选择订阅。这一成功的推出展示了创新解决方案的力量，帮助 DexCom 扩大了客户基础。公司还通过在特定市场利用战略分销商，每年扩展一到两个市场，进一步推动国际增长。</p>
<p>DexCom 的产品管道由创新驱动，其庞大的可寻址市场将确保业务在未来许多年中持续实现收入和利润的稳步增长。</p>

德康医疗

斯凯奇

史赛克

<p>本文讨论了三只适合长期投资的成长股：斯凯奇、史赛克和德康医疗。斯凯奇计划通过国际扩张和直接面向消费者的增长，到 2026 年实现 100 亿美元的销售额。史赛克是一家医疗技术公司，持续增加收入和股息，目标是实现 11% 的年度有机销售增长。德康医疗专注于糖尿病管理技术，受益于全球糖尿病发病率的上升。这些公司展现出强劲的增长潜力，适合希望随着时间积累财富的投资者</p>

<p>The best way to grow your wealth and better prepare yourself for retirement is to accumulate shares of solid growth stocks to own for the long term. As these companies steadily grow their revenue and profits, they become more valuable, and investors will be willing to pay more for them. As time goes by, their share prices will continue rising, thereby netting you attractive capital gains as you witness a consistent increase in the value of your investment portfolio.</p>
<div class="lb-trans"><p>增加财富并更好地为退休做准备的最佳方法是积累优质成长股，以便长期持有。随着这些公司稳定地增长其收入和利润，它们的价值也会随之提升，投资者愿意为其支付更高的价格。随着时间的推移，它们的股价将持续上涨，从而为您带来可观的资本收益，同时您也会看到投资组合价值的持续增长。</p>
</div><p>Better yet, you should select companies that are not only suitable for owning over years, but for life. Such businesses need to have a few important defining characteristics. They should exhibit a strong track record of growth, possess a recognizable brand that can command loyalty, and enjoy catalysts that can allow the business to grow steadily over time.</p>
<div class="lb-trans"><p>更好的是，您应该选择那些不仅适合多年持有，而且适合终身持有的公司。这些企业需要具备几个重要的定义特征。它们应该展现出强劲的增长记录，拥有能够赢得忠诚度的知名品牌，并享有能够使业务随着时间稳步增长的催化剂。</p>
</div><p>With these crucial ingredients in place, here are three solid growth stocks that you can contemplate buying.</p>
<div class="lb-trans"><p>在这些关键要素到位的情况下，以下是您可以考虑购买的三只优质成长股。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MDg3NTYvY29udGludW91cy1nbHVjb3NlLW1vbml0b3IuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F808756%2Fcontinuous-glucose-monitor.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty images.</p>
<div class="lb-trans"><p>图片来源：Getty images。</p>
</div><h2>1. Skechers</h2>
<div class="lb-trans"><h2>1. Skechers</h2>
</div><p><strong>Skechers</strong>(SKX 0.33%) designs, manufactures and markets a range of performance apparel and footwear for men, women, and children. The company sells its products through approximately 5,300 retail stores worldwide in more than 180 countries. Skechers has successfully grown its revenue and net income over the years, as shown in the table.</p>
<div class="lb-trans"><p><strong>Skechers</strong>(SKX 0.33%) 设计、制造和销售一系列适合男性、女性和儿童的运动服装和鞋类。该公司通过全球超过 180 个国家的约 5300 家零售店销售其产品。Skechers 多年来成功地增长了其收入和净利润，如下表所示。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$7.4 billion</td>
<td>$8 billion</td>
<td>$9 billion</td>
</tr>
<tr>
<td>Operating income</td>
<td>$546.6 million</td>
<td>$784.7 million</td>
<td>$904.3 million</td>
</tr>
<tr>
<td>Net income</td>
<td>$373 million</td>
<td>$545.7 million</td>
<td>$639.5 million</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>($120.7 million)</td>
<td>$907.4 million</td>
<td>No info</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>74 亿美元</td>
<td>80 亿美元</td>
<td>90 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>5.466 亿美元</td>
<td>7.847 亿美元</td>
<td>9.043 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>3.73 亿美元</td>
<td>5.457 亿美元</td>
<td>6.395 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>(1.207 亿美元)</td>
<td>9.074 亿美元</td>
<td>无信息</td>
</tr>
</tbody>
</table>
</div><p>Data source: Skechers. Fiscal years end Dec. 31.</p>
<div class="lb-trans"><p>数据来源：Skechers。财政年度截至 12 月 31 日。</p>
</div><p>Chief operating officer David Weinberg attributed the performance to Skechers' strong product line, which emphasizes comfort, style, and quality at an affordable price. CEO Robert Greenberg added that Skechers' wide portfolio of products appeals to different ages and genders, and its performance division targeting sports such as basketball, soccer, and golf still has significant global growth potential.</p>
<div class="lb-trans"><p>首席运营官 David Weinberg 将业绩归因于 Skechers 强大的产品线，强调舒适、风格和以合理价格提供的质量。首席执行官 Robert Greenberg 补充说，Skechers 广泛的产品组合吸引了不同年龄和性别的消费者，其针对篮球、足球和高尔夫等运动的表现部门仍具有显著的全球增长潜力。</p>
</div><p>Skechers outlined its growth plan to hit $10 billion in sales by 2026. The plan involves three key pillars: international expansion, direct-to-consumer (DTC) sales growth, and domestic growth. The company is aiming for low-to-mid-teens international sales growth through the expansion of its e-commerce platforms in new markets while diversifying its product offering.</p>
<div class="lb-trans"><p>Skechers 概述了其到 2026 年实现 100 亿美元销售额的增长计划。该计划涉及三个关键支柱：国际扩张、直接面向消费者（DTC）销售增长和国内增长。公司计划通过在新市场扩展其电子商务平台，同时多样化其产品供应，来实现低至中等的国际销售增长。</p>
</div><p>Investors can take heart in knowing that management has outlined an effective multiyear growth plan and made appropriate investments to handle stronger demand in the future.</p>
<div class="lb-trans"><p>投资者可以放心，管理层已经制定了有效的多年度增长计划，并进行了适当的投资，以应对未来更强劲的需求。</p>
</div><h2>2. Stryker</h2>
<div class="lb-trans"><h2>2. Stryker</h2>
</div><p><strong>Stryker</strong>(SYK -0.70%) is a medical technology company offering products and services for the medical and surgical equipment, neurotechnology, and orthopedics segments. Stryker has reported consistent growth in revenue, net income and free cash flow over the years, as shown in the table. Note that investors should pay attention to net income excluding exceptional items to get a better sense of the growth of the company's core business.</p>
<div class="lb-trans"><p><strong>Stryker</strong>(SYK -0.70%) 是一家医疗技术公司，提供医疗和外科设备、神经技术和骨科领域的产品和服务。Stryker 多年来在收入、净收入和自由现金流方面报告了持续增长，如下表所示。请注意，投资者应关注不包括特殊项目的净收入，以更好地了解公司核心业务的增长情况。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$18.449 billion</td>
<td>$20.498 billion</td>
<td>$22.595 billion</td>
</tr>
<tr>
<td>Operating income</td>
<td>$2.841 billion</td>
<td>$3.888 billion</td>
<td>$3.689 billion</td>
</tr>
<tr>
<td>Net income</td>
<td>$2.358 billion</td>
<td>$3.165 billion</td>
<td>$2.993 billion</td>
</tr>
<tr>
<td>Net income (ex EI)</td>
<td>$2.628 billion</td>
<td>$3.210 billion</td>
<td>$3.970 billion</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$2.036 billion</td>
<td>$3.136 billion</td>
<td>$3.487 billion</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>184.49 亿美元</td>
<td>204.98 亿美元</td>
<td>225.95 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>28.41 亿美元</td>
<td>38.88 亿美元</td>
<td>36.89 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>23.58 亿美元</td>
<td>31.65 亿美元</td>
<td>29.93 亿美元</td>
</tr>
<tr>
<td>净收入（不含特殊项目）</td>
<td>26.28 亿美元</td>
<td>32.10 亿美元</td>
<td>39.70 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>20.36 亿美元</td>
<td>31.36 亿美元</td>
<td>34.87 亿美元</td>
</tr>
</tbody>
</table>
</div><p>Data source: Stryker. Fiscal years end Dec. 31. EI stands for &#34;exceptional items.&#34;</p>
<div class="lb-trans"><p>数据来源：Stryker。财政年度截至 12 月 31 日。EI 代表 “特殊项目”。</p>
</div><p>This consistent free cash flow generation allowed the medical technology company to increase its dividend without fail since 2009. Stryker's most recent quarterly dividend stood at $0.84, a 5% year-over-year increase over the $0.80 paid out a year ago.</p>
<div class="lb-trans"><p>这种持续的自由现金流生成使得这家医疗技术公司自 2009 年以来能够不断增加其股息。Stryker 最近的季度股息为 0.84 美元，比一年前的 0.80 美元增长了 5%。</p>
</div><p>The company looks set to continue growing, with strong demand reported for its products in the markets it is present in. The business expects organic sales growth in the range of 8% to 9% for 2025 and has a long-term organic sales growth target of around 11% per annum, as announced during its 2023 Investor Day. The business is also growing through acquisitions that help to bolster its portfolio of products and services.</p>
<div class="lb-trans"><p>该公司看起来将继续增长，报告显示其产品在所处市场的需求强劲。该业务预计 2025 年的有机销售增长将在 8% 到 9% 之间，并在 2023 年投资者日上宣布了长期有机销售增长目标约为每年 11%。该业务还通过收购来增长，以增强其产品和服务组合。</p>
</div><p>The 2023 Investor Day also highlighted steady operating margin expansion of around two percentage points this year and around 0.3 percentage points annually, with adjusted earnings per share registering double-digit growth. Management also targets to convert around 70% to 80% of its adjusted net earnings into free cash flow, which should help to power the continued increase in Stryker's annual dividend.</p>
<div class="lb-trans"><p>2023 年投资者日还强调了今年约两个百分点的稳定营业利润率扩张和每年约 0.3 个百分点的增长，调整后的每股收益实现了两位数的增长。管理层还计划将约 70% 到 80% 的调整后净收益转化为自由现金流，这将有助于推动 Stryker 年度股息的持续增长。</p>
</div><h2>3. DexCom</h2>
<div class="lb-trans"><h2>3. DexCom</h2>
</div><p><strong>DexCom</strong>(DXCM 0.64%) is a medical device company that utilizes technology to help diabetes patients track their glucose levels. DexCom manufactures continuous glucose monitors (CGMs) that offer personalized solutions to its customers.</p>
<div class="lb-trans"><p><strong>DexCom</strong>(DXCM 0.64%) 是一家医疗设备公司，利用技术帮助糖尿病患者跟踪其葡萄糖水平。DexCom 制造连续血糖监测仪（CGM），为其客户提供个性化解决方案。</p>
</div><p>With diabetes numbers increasing globally and projected to hit 783 million by 2045 for adults aged 20 to 79, DexCom has witnessed increasing demand for its CGM solutions. The company reported consistent revenue, net income and free cash flow growth from 2022 to 2024, as shown in the table.</p>
<div class="lb-trans"><p>随着全球糖尿病患者数量的增加，预计到 2045 年 20 至 79 岁成年人将达到 7.83 亿，DexCom 的 CGM 解决方案需求不断增加。该公司报告了 2022 年至 2024 年期间收入、净收入和自由现金流的持续增长，如下表所示。</p>
</div><table>
<thead>
<tr>
<th>Metric</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$2.910 billion</td>
<td>$3.622 billion</td>
<td>$4.033 billion</td>
</tr>
<tr>
<td>Operating income</td>
<td>$391.2 million</td>
<td>$597.7 million</td>
<td>$600 million</td>
</tr>
<tr>
<td>Net income</td>
<td>$341.2 million</td>
<td>$541.5 million</td>
<td>$576.2 million</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>$304.7 million</td>
<td>$511.9 million</td>
<td>$630.7 million</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>指标</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>收入</td>
<td>29.10 亿美元</td>
<td>36.22 亿美元</td>
<td>40.33 亿美元</td>
</tr>
<tr>
<td>营业收入</td>
<td>3.912 亿美元</td>
<td>5.977 亿美元</td>
<td>6 亿美元</td>
</tr>
<tr>
<td>净收入</td>
<td>3.412 亿美元</td>
<td>5.415 亿美元</td>
<td>5.762 亿美元</td>
</tr>
<tr>
<td>自由现金流</td>
<td>3.047 亿美元</td>
<td>5.119 亿美元</td>
<td>6.307 亿美元</td>
</tr>
</tbody>
</table>
</div><p>Data source: DexCom. Fiscal years end Dec. 31.</p>
<div class="lb-trans"><p>数据来源：DexCom。财政年度截至 12 月 31 日。</p>
</div><p>For 2025, DexCom is projecting total revenue of $4.6 billion, which will represent 14% year-over-year growth.</p>
<div class="lb-trans"><p>对于 2025 年，DexCom 预计总收入为 46 亿美元，这将代表 14% 的同比增长。</p>
</div><p>It's still early days for the company as it drives CGM to become the standard of care for all stages of insulin use. DexCom grew its user base by around 25% in 2024 to approximately 2.8 million to 2.9 million customers globally, but management believes that this is just the tip of the iceberg.</p>
<div class="lb-trans"><p>对于公司来说，推动连续血糖监测（CGM）成为所有胰岛素使用阶段的标准护理仍然处于早期阶段。DexCom 在 2024 年将其用户基础增长了约 25%，全球客户数量达到约 280 万至 290 万，但管理层认为这只是冰山一角。</p>
</div><p>In the U.S. alone, there are more than 4.5 million people on insulin who have reimbursement (i.e., they can claim insurance) but are not on CGM. In addition, the US market size for type 2 non-insulin patients is greater than 25 million, of which the current CGM penetration rate is just 5%. And we are not even talking about the prediabetes market, which is estimated at around 98 million people with a less than 1% CGM penetration.</p>
<div class="lb-trans"><p>仅在美国，就有超过 450 万人正在使用胰岛素并且可以报销（即，他们可以申请保险），但并未使用 CGM。此外，2 型非胰岛素患者的美国市场规模超过 2500 万，而当前 CGM 的渗透率仅为 5%。我们甚至还没有谈到糖尿病前期市场，估计约有 9800 万人，CGM 的渗透率不到 1%。</p>
</div><p>Based on these numbers, it's clear that DexCom still has a long growth runway to tackle the diabetes scourge.</p>
<div class="lb-trans"><p>根据这些数据，显然 DexCom 仍然有很长的增长空间来应对糖尿病的困扰。</p>
</div><p>The company's Stelo product was approved back in March 2024 and is the first glucose biosensor in the U.S. cleared for use without a prescription. Since its launch in August last year, the product now has 140,000 users, with the majority signing up for a subscription. This successful launch shows the power of innovative solutions that are helping to boost DexCom's customer base. The company is also extending its international growth by expanding into one to two markets per year by leveraging strategic distributors in select markets.</p>
<div class="lb-trans"><p>该公司的 Stelo 产品于 2024 年 3 月获得批准，是美国首个获准无处方使用的葡萄糖生物传感器。自去年 8 月推出以来，该产品现已拥有 14 万用户，其中大多数选择订阅。这一成功的推出展示了创新解决方案的力量，帮助 DexCom 扩大了客户基础。公司还通过在特定市场利用战略分销商，每年扩展一到两个市场，进一步推动国际增长。</p>
</div><p>DexCom's pipeline of products is powered by innovation, and its large total addressable market will ensure that the business enjoys steadily rising revenue and profits for many more years.</p>
<div class="lb-trans"><p>DexCom 的产品管道由创新驱动，其庞大的可寻址市场将确保业务在未来许多年中持续实现收入和利润的稳步增长。</p>
</div>

3 只值得长期买入并持有的成长股